BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35135231)

  • 1. Identification of novel immunomodulators in lung squamous cell carcinoma based on transcriptomic data.
    Lin X; Li X; Ma B; Hang L
    Math Biosci Eng; 2022 Jan; 19(2):1843-1860. PubMed ID: 35135231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 13-gene signature to predict the prognosis and immunotherapy responses of lung squamous cell carcinoma.
    Yang Q; Gong H; Liu J; Ye M; Zou W; Li H
    Sci Rep; 2022 Aug; 12(1):13646. PubMed ID: 35953696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and validation of a novel immune-related prognostic model in lung squamous cell carcinoma.
    Liu Z; Wan Y; Qiu Y; Qi X; Yang M; Huang J; Zhang Q
    Int J Med Sci; 2020; 17(10):1393-1405. PubMed ID: 32624696
    [No Abstract]   [Full Text] [Related]  

  • 4. Construction of a predictive model for immunotherapy efficacy in lung squamous cell carcinoma based on the degree of tumor-infiltrating immune cells and molecular typing.
    Yang L; Wei S; Zhang J; Hu Q; Hu W; Cao M; Zhang L; Wang Y; Wang P; Wang K
    J Transl Med; 2022 Aug; 20(1):364. PubMed ID: 35962453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A robust signature associated with patient prognosis and tumor immune microenvironment based on immune-related genes in lung squamous cell carcinoma.
    Zhou H; Zhang H; Shi M; Wang J; Huang Z; Shi J
    Int Immunopharmacol; 2020 Nov; 88():106856. PubMed ID: 32777677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrative Genomic and Transcriptomic Analyses of Tumor Suppressor Genes and Their Role on Tumor Microenvironment and Immunity in Lung Squamous Cell Carcinoma.
    Kim A; Lim SM; Kim JH; Seo JS
    Front Immunol; 2021; 12():598671. PubMed ID: 33717076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Novel Immune-Related Seventeen-Gene Signature for Predicting Early Stage Lung Squamous Cell Carcinoma Prognosis.
    Fan T; Lu Z; Liu Y; Wang L; Tian H; Zheng Y; Zheng B; Xue L; Tan F; Xue Q; Gao S; Li C; He J
    Front Immunol; 2021; 12():665407. PubMed ID: 34177903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction and Validation of Prognostic Regulation Network Based on RNA-Binding Protein Genes in Lung Squamous Cell Carcinoma.
    Zhao S; Liu Q; Li J; Hu C; Cao F; Ma W; Gao J
    DNA Cell Biol; 2021 Dec; 40(12):1563-1583. PubMed ID: 34931870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Classification of the immune microenvironment associated with 12 cell death modes and construction of a prognostic model for squamous cell lung cancer.
    Bin Y; Ding P; Liu L; Tong F; Dong X
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):9051-9070. PubMed ID: 37169931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
    Li N; Wang J; Zhan X
    Front Immunol; 2021; 12():752643. PubMed ID: 34887858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment of a prognostic model toward lung squamous cell carcinoma based on m
    Wang Y; Liu Y; Wang R; Cao F; Guan Y; Chen Y; An B; Qin S; Yao S
    Physiol Genomics; 2023 Oct; 55(10):427-439. PubMed ID: 37575065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Four hub genes regulate tumor infiltration by immune cells, antitumor immunity in the tumor microenvironment, and survival outcomes in lung squamous cell carcinoma patients.
    Zhang T; Yang H; Sun B; Yao F
    Aging (Albany NY); 2021 Jan; 13(3):3819-3842. PubMed ID: 33428598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer Stemness-Based Prognostic Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
    Li N; Li Y; Zheng P; Zhan X
    Front Endocrinol (Lausanne); 2021; 12():755805. PubMed ID: 34745015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Combined Detection of Immune Genes for Predicting the Prognosis of Patients With Non-Small Cell Lung Cancer.
    Tian WJ; Liu SS; Li BR
    Technol Cancer Res Treat; 2020; 19():1533033820977504. PubMed ID: 33256552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and validation of a novel immune-related prognostic signature in lung squamous cell carcinoma patients.
    Liu X; Zhao D; Shan Y; Cui W; Xie Q; Jiang J; Peng W; Zhang C; Duan C
    Sci Rep; 2022 Dec; 12(1):20737. PubMed ID: 36456645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a Clinical Prognostic Model for Metabolism-Related Genes in Squamous Lung Cancer and Correlation Analysis of Immune Microenvironment.
    Zhuang Z; Gao C
    Biomed Res Int; 2022; 2022():6962056. PubMed ID: 36110123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of immune subtypes and overall survival in lung squamous cell carcinoma.
    Su X; Gao H; Qi Z; Xu T; Wang G; Luo H; Cheng P
    Curr Med Res Opin; 2023 Feb; 39(2):289-298. PubMed ID: 36245361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune signature of T follicular helper cells predicts clinical prognostic and therapeutic impact in lung squamous cell carcinoma.
    Xu F; Zhang H; Chen J; Lin L; Chen Y
    Int Immunopharmacol; 2020 Apr; 81():105932. PubMed ID: 31836430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a new risk score model based on hypoxia and EMT-related genes for predicting lung squamous cell carcinoma prognosis.
    Zhuang X; Yu S; Yang S; Chen J; Feng J
    Medicine (Baltimore); 2023 Nov; 102(44):e35572. PubMed ID: 37933024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HTR2B as a novel biomarker of chronic obstructive pulmonary disease with lung squamous cell carcinoma.
    Li Y; Wang Y; Wu R; Li P; Cheng Z
    Sci Rep; 2024 Jun; 14(1):13206. PubMed ID: 38851806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.